Еверолимус Сандоз

Everolimus Sandoz is an oral immunosuppressant and antineoplastic agent used to manage organ transplant rejection and certain cancers. It belongs to the mTOR inhibitor class, providing targeted therapy with broad applications in oncology and transplant medicine.

Everolimus is primarily used to prevent organ transplant rejection in kidney and heart transplant patients. It is also prescribed for advanced renal cell carcinoma, neuroendocrine tumors of pancreatic origin, and tuberous sclerosis complex-associated renal angiomyolipoma. The medication works by modulating immune responses and inhibiting tumor growth pathways.

Everolimus helps reduce the activity of the immune system to prevent organ rejection after a transplant. In cancer treatment, it slows the growth of certain tumors by interfering with cell signaling pathways. Patients may experience improved symptom control and disease stabilization over time.

Everolimus should be taken exactly as prescribed, typically once daily at the same time each day. It is important to attend regular medical check-ups to monitor kidney function, blood cell counts, and lipid levels. Avoid grapefruit and grapefruit juice, as they can affect how the medication is processed in the body.

Everolimus may interact with strong CYP3A4 inhibitors or inducers, such as certain antifungals, antibiotics, or anticonvulsants, which can alter its effectiveness. Caution is advised when combining with other immunosuppressants or medications that affect blood cell counts. Alcohol should be consumed in moderation, if at all.